Results 171 to 180 of about 1,505,406 (304)

Treatment approach for diabetes mellitus type 2 in a 70-year-old male: A case report. [PDF]

Medicine (Baltimore)
Ndalela N, Lingela AN, Mpofu L.
europepmc   +1 more source

Innovative insights into the effects of a high‐sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study

Animal Models and Experimental Medicine, EarlyView.
Histologic assessment of pancreatic tissues using the H&E method (Scale bar = 100 μm. Images were captured at 400×). A high‐sucrose diet induced structural damage in pancreatic tissue, whereas empagliflozin treatment markedly improved these histological alterations.
Emad Gholami, Ali Fardin, Fazeleh Iranshahi, Alireza Malek, Ali Saravani, Faranaz Aghvami, Houman Parsaei, Habib Yaribeygi   +7 more
wiley   +1 more source

Phenotypic characteristics of diabetic neuropathic pain and factors associated in patients with Diabetes Mellitus-type 2. [PDF]

J Diabetes Investig
De Sola H, Dueñas M, Failde I, Palomo-Osuna J, Naranjo C, Salazar A.   +5 more
europepmc   +1 more source

Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System—A Multicenter Cohort Study in 163 Patients

Annals of Neurology, EarlyView.
Objective The aim was to determine patient, disease, and treatment characteristics associated with outcome in patients with primary angiitis of the central nervous system (PACNS) in a large multicenter German cohort. Methods In a retrospective, observational cohort study, we analyzed 163 adult patients who met the diagnostic criteria for PACNS.
Anna Lena Fisse, Nadine Bonberg, Carolin Beuker, Claudia Pfeuffer, Andreas Heidenreich, Christina Krüger, Milani Deb‐Chatterji, Jana Becker, Stefan T. Gerner, Clemens Küpper, Louisa Nitsch, Roxane‐Isabelle Kestner, Lars Udo Krause, Juliane Herm, Alexander Katalinic, André Karch, Ralf Gold, Heinz Wiendl, Wolf‐Rüdiger Schäbitz, Gabor C. Petzold, Waltraud Pfeilschifter, Marius Ringelstein, Thorsten R. Doeppner, Lars Kellert, Hagen B. Huttner, Markus Kraemer, Tim Magnus, Karl Georg Haeusler, Heike Minnerup, Jens Minnerup   +29 more
wiley   +1 more source

Estimation of the Burden of Disease Due to Diabetes Mellitus Type 2 in the Population of Tabasco During the Period 2013-2023. [PDF]

Int J Environ Res Public Health
Hernández-Bartolo DR, Quiroz-Gomez S, Guzmán-Priego CG, Celorio-Méndez KDS, Juárez-Rojop IE, Ble Castillo JL, Guzmán-Moreno M, Romero Tapia SJ, Jiménez-Sastré A, López-Villarreal SM, Rodríguez-Luis OE, Villarreal-García LE.   +11 more
europepmc   +1 more source

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy

Annals of Neurology, EarlyView.
Objective Exenatide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has neuroprotective effects in preclinical models of multiple system atrophy (MSA). We investigated these effects in a proof‐of‐concept clinical trial. Methods In this single‐center, randomized, open label trial, participants with MSA were randomly assigned (1:1) to receive ...
Nirosen Vijiaratnam, Christine Girges, Martin Wiegand, Claudia Ismail, Alexandra Lameirinhas, Alison Yarnall, Cameron Kirk, Silvia Del‐Din, Lynn Rochester, Christopher Kobylecki, Gareth Ambler, Simon Skene, Henry Houlden, Viorica Chelban, Amanda Heslegrave, Wendy Phillips, Alan Whone, Niall Quinn, Christian Lambert, Charlotte Dore, Huw R. Morris, Mathew H. Horrocks, Ji Eun Lee, Judi O'Shaughnessy, Yazhou Li, Nigel H. Greig, Sonia Gandhi, Vincenzo Libri, Dilan Athauda, Tom Foltynie   +29 more
wiley   +1 more source

Impact of diabetes mellitus type-2 on the outcomes following mitral transcatheter edge-to-edge repair (TEER): A meta-analysis. [PDF]

Am Heart J Plus
Chigurupati HD, Neppala S, Chikatimalla R, Fath A, Upreti P, Bolte J, Naveed MA, Rao A, Altaee O, Sattar Y, Desai R, DeFronzo RA, Rana JS, Paul TK.   +13 more
europepmc   +1 more source

Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2. [PDF]

Cardiovasc Diabetol, 2023
Kogan A, Grupper A, Sabbag A, Ram E, Jamal T, Nof E, Fisman EZ, Levin S, Beinart R, Frogel J, Raanani E, Sternik L.   +11 more
europepmc   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Blood Metabolic Biomarkers of Diabetes Mellitus Type 2 in Aged Adults Determined by a UPLC-MS Metabolomic Approach. [PDF]

Metabolites
Simón A, Bordonaba-Bosque D, Montero O, Solano-Castán J, Caro I.   +4 more
europepmc   +1 more source